Ipsen North America
在场
Ipsen North America 的所有者是 Ipsen.
是其中之一......
Ipsen 是一家在股票代码 IPN (FR) 下上市的公司。
Ipsen 在 5 个国家有直接业务。Ipsen 拥有 4家子公司，其中包括 Ipsen Iberica、Ipsen North America 和 Ipsen UK。
他们在：
高管
查看带有其 19 名主要高管的组织结构图
Ipsen North America 搜索最多的简介
- Keira Driansky, Executive Vice President and President
- Ed Dybka, General Manager, Ipsen Canada
- Elizabeth Kalina, Vice President, Corporate Affairs and Patient Se...
高管在Ipsen变化
- Josep CatllàJosep Catllà 将于20248月19作为 Executive Vice President and Chief Corporate Affairs Officer 加入公司 (新闻发布的2024六月7号).
- Stewart Campbell, Executive Vice President, President, North America, 将于 20245月13 退休 (新闻发布的2024五月2号).
- Keira DrianskyKeira Driansky 将于20245月13作为 Executive Vice President and President of North America 加入公司 (新闻发布的2024五月2号).
创建提醒
跟踪 Ipsen North America 的高管变动
药店
Ipsen 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Ipsen North America 的最新新闻稿
- Ipsen appoints Keira Driansky as EVP, President of North America - United States
- Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA - United States
- Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC - United States
- Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - United States
- US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva - United States
- Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
- https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2023/03/02171831/Ipsen-completes-acquisition-of-Albireo-Press-Release-03-23.pdf
- Ipsen presents Phase III NAPOLI 3 trial at ASCO GI
- Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva - Ipsen US
- View more press releases Close
通过电子邮件
